Evaluating anti-viral drug selection and treatment duration in HBeAg-negative chronic hepatitis B: A cost-effectiveness analysis

Alimentary Pharmacology and Therapeutics

Volumn 27, Issue 12, 2008, Pages 1240-1252

  Veenstra, D L ^a   Spackman, D E ^a   Bisceglie, A ^b   Kowdley, K V ^c   Gish, R G ^d  

^a UNIVERSITY OF WASHINGTON   (United States)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BENAROYA RESEARCH INSTITUTE   (United States)

^d CALIFORNIA PACIFIC MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR; ENTECAVIR; HEPATITIS B(E) ANTIGEN; LAMIVUDINE;

ANTIVIRAL RESISTANCE; ARTICLE; CHRONIC HEPATITIS; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DISEASE COURSE; DRUG COST; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIFE EXPECTANCY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; MORTALITY; PRIORITY JOURNAL; QUALITY OF LIFE; REIMBURSEMENT; SENSITIVITY ANALYSIS; SEROCONVERSION; TREATMENT DURATION;

ADENINE; ANTIVIRAL AGENTS; COST-BENEFIT ANALYSIS; EPIDEMIOLOGIC METHODS; GUANINE; HEPATITIS B E ANTIGENS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; PHOSPHONIC ACIDS;

EID: 43849091109     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03691.x     Document Type: Article

References (56)

1. Custer B, Sullivan SD, Hazlet TK, Iloeje U, Veenstra DL, Kowdley KV. Global epidemiology of hepatitis B virus. J Clin Gastroenterol 2004 38 : S158 68.
2. Lee TA, Veenstra DL, Iloeje UH, Sullivan SD. Cost of chronic hepatitis B infection in the United States. J Clin Gastroenterol 2004 38 : S144 7.
3. Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med 2004 350 : 1118 29.
4. Chu CJ, Keeffe EB, Han SH, et al. Prevalence of HBV precore/core promoter variants in the United States. Hepatology 2003 38 : 619 28.
5. Gish RG, Gadano AC. Chronic hepatitis B: current epidemiology in the Americas and implications for management. J Viral Hepat 2006 13 : 787 98.
6. Huang S, Shallow S, Stier D, et al. Characteristics of persons with Chronic Hepatitis B - San Francisco, California, 2006. MMWR Morb Mortal Wkly Rep 2007 56 : 446 8.
7. Lai CL, Ratziu V, Yuen MF, Poynard T. Viral hepatitis B. Lancet 2003 362 : 2089 94.
8. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrhosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 2006 130 : 678 86.
9. Liaw YF, Tai DI, Chu CM, et al. Early detection of hepatocellular carcinoma in patients with chronic type B hepatitis. A prospective study. Gastroenterology 1986 90 : 263 7.
10. Chen CJ, Yang HI, Su J, et al. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA 2006 295 : 65 73.
11. Perrillo RP, Gish RG, Peters M, et al. Chronic hepatitis B: a critical appraisal of current approaches to therapy. Clin Gastroenterol Hepatol 2006 4 : 233 48.
12. Mommeja-Marin H, Mondou E, Blum MR, Rousseau F. Serum HBV DNA as a marker of efficacy during therapy for chronic HBV infection: analysis and review of the literature. Hepatology 2003 37 : 1309 19.
13. Lok AS. The maze of treatments for hepatitis B. N Engl J Med 2005 352 : 2743 6.
14. Lok A, McMahon B. AASLD Practice Guidelines: Chronic Hepatitis B. Hepatology 2007 45 : 507 39.
15. Veenstra DL, Sullivan SD, Clarke L, et al. Cost Effectiveness of Entecavir vs. Lamivudine with Adefovir Salvage in HBeAg-Positive Chronic Hepatitis B. Pharmacoeconomics 2007 25 : 963 77.
16. Lipscomb J, Weinstein MC, Torrance GW. Time Preference. In : Gold MR, Siegel JE, Russell LB, Weinstein MC, eds. Cost-effectiveness in Health and Medicine. New York : Oxford University Press, 1996 : 214 46.
17. Lai C-L, Shouval D, Lok AS, et al. Entecavir vs. Lamivudine for Patients with HBeAg-Negative Chronic Hepatitis B. N Engl J Med 2006 354 : 1011 20.
18. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-negative chronic hepatitis B. N Engl J Med 2003 348 : 800 7.
19. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B. N Engl J Med 2005 352 : 2673 81.
20. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology 2002 35 : 1522 7.
21. Fattovich G, Pantalena M, Zagni I, Realdi G, Schalm SW, Christensen E. Effect of hepatitis B and C virus infections on the natural history of compensated cirrhosis: a cohort study of 297 patients. Am J Gastroenterol 2002 97 : 2886 95.
22. de Jongh FE, Janssen HL, de Man RA, Hop WC, Schalm SW, van Blankenstein M. Survival and prognostic indicators in hepatitis B surface antigen-positive cirrhosis of the liver. Gastroenterology 1992 103 : 1630 5.
23. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir dipivoxil and pegylated interferon alfa-2a for the treatment of chronic hepatitis B: a systematic review and economic evaluation. Health Technol Assess 2006 10 : iii iv, xi xiv, 1 183.
24. Kanwal F, Gralnek IM, Martin P, Dulai GS, Farid M, Spiegel BM. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med 2005 142 : 821 31.
25. Vassiliadis T, Nikolaidis N, Giouleme O, et al. Adefovir dipivoxil added to ongoing lamivudine therapy in patients with lamivudine-resistant hepatitis B e antigen-negative chronic hepatitis B. Aliment Pharmacol Ther 2005 21 : 531 7.
26. Lampertico P, Vigano M, Manenti E, Iavarone M, Lunghi G, Colombo M. Adefovir rapidly suppresses hepatitis B in HBeAg-negative patients developing genotypic resistance to lamivudine. Hepatology 2005 42 : 1414 9.
27. Rapti I, Dimou E, Mitsoula P, Hadziyannis SJ. Adding-on vs. switching-to adefovir therapy in lamivudine-resistant HBeAg-negative chronic hepatitis B. Hepatology 2007 45 : 307 13.
28. Hadziyannis S, Sevastianos V, Rapti I, Tassopoulos N. Sustained biochemical and virological remission after discontinuation of 4 to 5 years of adefovir dipivoxil (ADV) treatment in HBe-Ag-negative chronic hepatitis B. 57th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD), Boston, MA, 27-31 October 2006.
29. Hadziyannis SJ, Tassopoulos NC, Heathcote EJ, et al. Long-term therapy with adefovir dipivoxil for HBeAg-negative chronic hepatitis B for up to 5 years. Gastroenterology 2006 131 : 1743 51.
30. EASL. EASL International Consensus Conference on Hepatitis B. 13-14 September, 2002: Geneva, Switzerland. Consensus statement (short version). J Hepatol 2003 38 : 533 40.
31. Bonino F, Rosina F, Rizzetto M, et al. Chronic hepatitis in HBsAg carriers with serum HBV-DNA and anti-HBe. Gastroenterology 1986 90 : 1268 73.
32. Brunetto MR, Giarin M, Oliveri F, et al. 'e' antigen defective hepatitis B virus and course of chronic infection. J Hepatol 1991 13 (Suppl 4 S82 6.
33. Arias E. National Vital Statistics Reports, United States Life Tables, 2002, Vol. 53. Statistics, MD : National Center for Health, 2004.
34. Crowley S, Tognarini D, Desmond P, Lees M, Saal G. Introduction of lamivudine for the treatment of chronic hepatitis B: expected clinical and economic outcomes based on 4-year clinical trial data. J Gastroenterol Hepatol 2002 17 : 153 64.
35. Shepherd J, Jones J, Takeda A, Davidson P, Price A. Adefovir Dipivoxil and Pegylated Interferon Alfa-2a for the Treatment of Chronic Hepatitis B - A Systematic Review and Economic Evaluation. UK : National Institute for Health and Clinical Excellence, Southampton Health Technology Assessments Centre (SHTAC), 2005.
36. Kim WR, Poterucha JJ, Kremers WK, Ishitani MB, Dickson ER. Outcome of liver transplantation for hepatitis B in the United States. Liver Transpl 2004 10 : 968 74.
37. Kim WR, Veenstra DL, Iloeje UH, et al. The natural history of chronic hepatitis B infection: a new computer simulation model to incorporate events subsequent to HBeAg seroconversion. Digestive Disease Week, Chicago, IL, 14-19 May, 2005.
38. Wong JB, Koff RS, Tine F, Pauker SG. Cost-effectiveness of interferon-alpha 2b treatment for hepatitis B e antigen-positive chronic hepatitis B. Ann Intern Med 1995 122 : 664 75.
39. Pwu RF, Chan KA. Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan. J Formos Med Assoc 2002 101 : 632 41.
40. Lai CL, Chang TT, Chao YC, et al. Entecavir 96-Week Data in HBeAg-Negative Chronic Hepatitis B. Manila, Philippines : Asian Pacific Association for the Study of the Liver, APASL, 2006.
41. Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004 351 : 1206 17.
42. Colonno R, Rose R, Pokornowski K, Baldick C, Klesczewski K, Tenney D. Assessment at three years shows high barrier to resistance is maintained in entecavir-treated nucleoside naïve patients while resistance emergence increases over time in lamivudine refractory patients. AASLD Annual Meeting, Boston, MA, 2006.
43. Colonno RJ, Rose R, Baldick CJ, et al. Entecavir resistance is rare in nucleoside naive patients with hepatitis B. Hepatology 2006 44 : 1656 65.
44. Di Marco V, Marzano A, Lampertico P, et al. Clinical outcome of HBeAg-negative chronic hepatitis B in relation to virological response to lamivudine. Hepatology 2004 40 : 883 91.
45. Salomon JA, Weinstein MC, Hammitt JK, Goldie SJ. Cost-effectiveness of treatment for chronic hepatitis C infection in an evolving patient population. JAMA 2003 290 : 228 37.
46. Chen PJ, Chen DS. Hepatitis B virus infection. N Engl J Med 1998 338 : 1312 author reply 1312-3.
47. AnalySource. Wholesale Acquisition Cost: AnalySource Inc. East Syracuse, NY : DMD America, 2007.
48. Levy AR, Kowdley KV, Iloeje U, et al. The impact of chronic hepatitis B on quality of life: a multinational study of utilities from infected and non-infected persons. Value Health 2007 PMID: 18179664.
49. Fenwick E, Claxton K, Sculpher M. Representing uncertainty: the role of cost-effectiveness acceptability curves. Health Econ 2001 10 : 779 87.
50. Fenwick E, Marshall DA, Levy AR, Nichol G. Using and interpreting cost-effectiveness acceptability curves: an example using data from a trial of management strategies for atrial fibrillation. BMC Health Serv Res 2006 6 : 52.
51. Yuen MF, Lai CL. Combination therapy for chronic hepatitis B: simultaneous or sequential? Am J Gastroenterol 2007 102 : 105 6.
52. McMahon BJ, Holck P, Bulkow L, Snowball M. Serologic and clinical outcomes of 1536 Alaska Natives chronically infected with hepatitis B virus. Ann Intern Med 2001 135 : 759 68.
53. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology 1997 112 : 463 72.
54. Bolondi L, Sofia S, Siringo S, et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 2001 48 : 251 9.
55. Lok AS, Lai CL, Leung N, et al. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003 125 : 1714 22.
56. Hoofnagle JH, Lau D. Chronic viral hepatitis - benefits of current therapies. N Engl J Med 1996 334 : 1470 1.